Simultaneous determination of acetylpuerarin and puerarin in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study following intravenous and oral administration

Sun, Deqing; Xue, Aiying; Wu, Jing; Zhang, Bin; Yu, Jinlong; Li, Qiang; Sun, Chenglong

doi:10.1016/j.jchromb.2015.05.009

Cited by 12 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ohwi. Puerarin (7,4′-dihydroxyisoflavone-8 β -glucopyranoside, Figure 1) is a major active ingredient of Radix Puerariae [2, 3]. A large number of pharmacological studies have indicated that puerarin has a protective effect upon the cardiovascular system.…”

Section: Introductionmentioning

confidence: 99%

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations

Song

Bai

Liu

et al. 2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of puerarin loaded carboxymethyl chitosan microspheres (Pue-CCMs). The differences in pharmacokinetics parameters of rats after intragastric administration of Pue-CCMs and puerarin were investigated using HPLC. To assess the protective effect of Pue-CCMs on myocardial injury in rats, serum levels of creatine kinase (CK), lactate dehydrogenase (LDH), total superoxide dismutase (T-SOD), and malondialdehyde (MDA) were measured, in addition to pathological examinations and immunohistochemical staining. Our present study has shown that the AUC0–t, Cmax, Tmax, MRT0–t of Pue-CCMs, and puerarin were 20.176 mg·h/L, 3.778 μg/mL, 1 h, 4.634 h and 9.474 mg·h/L, 2.618 μg/mL, 0.542 h, and 3.241 h, respectively. Pue-CCMs alleviated myocardial ischemic injury. Pretreatment with Pue-CCMs could significantly decrease CK, LDH, and MDA levels and increase T-SOD level in the serum. Pue-CCMs downregulated expression of the Bcl-2 associated X protein (Bax) and upregulated B-cell lymphoma-2 (Bcl-2) expression. Compared with puerarin group, the Pue-CCMs group could improve the oral bioavailability of puerarin. The protective effect of Pue-CCMs against myocardial injury was significantly greater than puerarin at the same dose. In summary, Pue-CCMs should be a qualified and promising candidate as a new oral preparation of puerarin.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations

Song

Bai

Liu

et al. 2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…It was found that LOV had a much lower C max (9.92 ± 2.43 ng/mL) and AUC 0-8h (9.99 ± 3.43 ng min/mL) than LOVA (299.28 ± 159.65 ng/mL and 583.01 ± 310.57 ng min/mL) in rat plasma. The reason for this might be that LOV was metabolized to LOVA after its absorption from the gastrointestinal tract, as has also been found for other ester compounds [20][21][22]. The t max (0.11 ± 0.05 h) of LOV was much shorter than that of 2.4 ± 0.5 h reported by Wang et al [13].…”

Section: Application To a Pharmacokinetic Studymentioning

confidence: 68%

Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC–MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension

Guo

Zhao

et al. 2016

Journal of Chromatography B

View full text Add to dashboard Cite

“…Using HPLC-MS/MS, Prasain et al found an AUC of 9.17 ± 4.87 mg·h/L in the serum of spontaneously hypertensive rats after oral administration of 50 mg/kg PUE [21]. In contrast, following intravenous administration of 15 mg/kg PUE, Sun et al found a plasma AUC of 6587.04 ± 1520.60 ng·h/mL using LC-MS/MS [22]. In the present study, the rat plasma AUC0-360 min was 5157.760 ± 449.934 µg·min/mL, 3510.49 ± 244.72 µg·min/mL, and 2196.95 ± 246.74 µg·min/mL following intraperitoneal injection of 80, 40, and 20 mg/kg PUE, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…This discrepancy may stem from the differences in detection method and sample processing. In our study, the serum was only diluted by PBS prior to icELISA analysis, but serum proteins must be precipitated with methanol or other organic solvents before HPLC or HPLC-MS [13,14,21,22], increasing the risk of PUE loss.…”

Section: Resultsmentioning

confidence: 99%

Pharmacokinetics and Tissue Distribution Kinetics of Puerarin in Rats Using Indirect Competitive ELISA

Kong

Wang

Shi

et al. 2017

Preprint

View full text Add to dashboard Cite

Puerarin (PUE) is a compound isolated from the roots of Pueraria lobata. We studied the pharmacokinetics and tissue distribution kinetics of PUE in Sprague-Dawley rats following intraperitoneal administration of three concentrations. Indirect competitive ELISA based on an anti-PUE monoclonal antibody was used to determine the concentration of PUE in the blood, heart, liver, spleen, lung, kidney, hippocampus, cerebral cortex, and striatum. The plasma and tissue distribution kinetic characteristics following a single injection of PUE (20, 40, and 80 mg/kg) were calculated using a non-compartment model. In the high-dose (80 mg/kg) and medium-dose (40 mg/kg) groups, the kinetic profile of PUE in blood and kidney samples showed two absorption peaks, while that of the other tissues showed only one peak. In the low-dose (20 mg/kg) group, there was only one peak, irrespective of the sample type. Pharmacokinetic parameters such as the area under the curve, Cmax, and Tmax varied according to the administered dose. AUC and Cmax values increased dose-dependently. PUE was widely distributed in areas of the brain such as the hippocampus, cerebral cortex, and striatum, providing a foundation for guiding the use of PUE in the treatment of cerebral ischaemic stroke and neurodegenerative diseases.

show abstract

Simultaneous determination of acetylpuerarin and puerarin in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study following intravenous and oral administration

Cited by 12 publications

References 21 publications

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations

A Novel Microspheres Formulation of Puerarin: Pharmacokinetics Study and In Vivo Pharmacodynamics Evaluations

Simultaneous determination of lovastatin and its metabolite lovastatin acid in rat plasma using UPLC–MS/MS with positive/negative ion-switching electrospray ionization: Application to a pharmacokinetic study of lovastatin nanosuspension

Pharmacokinetics and Tissue Distribution Kinetics of Puerarin in Rats Using Indirect Competitive ELISA

Contact Info

Product

Resources

About